NEW DELHI: Concord Biotech, backed by Rare Enterprises, has announced the price band for its initial public offering (IPO) at Rs 705-741 per share, aiming to raise Rs 1,550 crore.
The IPO will be open for public subscription from August 4 to August 8, as per the company's statement. The offering consists of 2.09 crore equity shares, offered entirely through an offer-for-sale (OFS) by Helix Investment Holdings Pte Limited, which is backed by private equity firm Quadria Capital. The eligible employees have also been given a reservation for subscriptions.